![Kevin Robert Pojasek](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kevin Robert Pojasek
Director/Miembro de la Junta en Ervaxx Ltd. .
Perfil
Kevin Robert Pojasek has worked as a Director at Ervaxx Ltd.
since 2018.
Cargos activos de Kevin Robert Pojasek
Empresas | Cargo | Inicio |
---|---|---|
Ervaxx Ltd.
![]() Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Director/Miembro de la Junta | 01/09/2018 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Ervaxx Ltd.
![]() Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Health Technology |
- Bolsa de valores
- Insiders
- Kevin Robert Pojasek